FIELD: medicine, pharmaceutics.
SUBSTANCE: described are new triazolopyrimidine derivatives of general formula (I): 
wherein R1 means hydrogen or alkyl; R2 means hydrogen; R3 means optionally substituted C3-8cycloalkyl, optionally substituted bridged monocyclic C6-cycloalkyl, optionally substituted phenyl, optionally substituted 6-member heterocyclyl containing one or two heteroatoms specified in O and N, etc., a pharmaceutical composition containing them, and using the compounds and composition for inhibiting the enzyme type 1 diacylglycerol-O-acyltransferase (DGAT) for treating type 2 diabetes mellitus, obesity, high plasma triglycerides, metabolic syndrome, etc.
EFFECT: there are presented new triazolopyrimidine derivatives.
11 cl, 73 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
| NEW PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AND APPLICATION THEREOF | 2014 |
|
RU2621709C2 |
| COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | 2007 |
|
RU2474576C2 |
| INHIBITORS OF CDK | 2011 |
|
RU2621674C2 |
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
| ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF FOR INHIBITING NOREPINEPHRINE, DOPAMINE AND SEROTONIN REUPTAKE | 2005 |
|
RU2388751C2 |
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
| REGULATORS OF DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND USE | 2019 |
|
RU2803499C1 |
